Successful treatment of resistant HCV in a patient with Child-Pugh B cirrhosis using sofosbuvir and glecaprevir/pibrentasvir
Authors:
- 5 July 2020
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 13 (7) , e232931
Abstract
Treatments for hepatitis C are now well tolerated with very high rates of sustained virological response and almost all patients have a suitable and effective treatment option. However, treatment options remain limited for a minority of patients and are limited for patients with Child-Pugh B or C cirrhosis due to the risk of decompensation with protease inhibitors. We present a case of successful treatment with glecaprevir/pibrentasvir (Maviret) and sofosbuvir in a patient with Child-Pugh B cirrhosis and resistant virus who had failed three previous attempts of treatment including two courses of direct acting antiviral agents and in whom liver transplantation was deemed unsuitable. We propose that the balance of risks favours a trial of treatment with protease inhibitors in some circumstances in patients with Child-Pugh B cirrhosis where no other suitable alternatives including treatment post liver transplantation are available/appropriate.Keywords
This publication has 8 references indexed in Scilit:
- Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort)Hepatology International, 2018
- Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical TrialsAntimicrobial Agents and Chemotherapy, 2018
- Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infectionJournal of Hepatology, 2018
- Sofosbuvir + Glecaprevir/Pibrentasvir in patients with difficult to treat HCV infection. Final results of the French compassionate useJournal of Hepatology, 2018
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionNew England Journal of Medicine, 2018
- In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirAntimicrobial Agents and Chemotherapy, 2017
- Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosisJournal of Hepatology, 2016
- Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGETJournal of Hepatology, 2015